Stockscreener 앱 받기
0.8432
1.55%
-0.0133
시간 외 거래:
.84
-0.0032
-0.38%
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Biotech Inc.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Zacks Research Issues Pessimistic Forecast for ONCY Earnings - MarketBeat
3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts - Sahm
Can Oncolytics Biotech (TSX:ONC) Unlock Its Next Catalyst? - Kalkine Media
HC Wainwright Has Bearish Estimate for ONCY FY2026 Earnings - MarketBeat
ONCY Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com Canada
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials - Yahoo Finance
BRIEF-Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer - Bitget
Oncolytics Biotech (ONCY) Advances Pelareorep Trial with Positiv - GuruFocus
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Form 8K Oncolytics Biotech Inc. For: 18 August By Investing.com - Investing.com Nigeria
Oncolytics receives FDA feedback on colorectal cancer study design - Investing.com
Oncolytics receives FDA feedback on colorectal cancer study design By Investing.com - Investing.com Canada
Oncolytics aligns with FDA on potential pivotal expansion of REO 033 in RAS‑mutant MSS colorectal cancer - TradingView
Oncolytics may seek accelerated approval using tumor response data - Stock Titan
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech (ONCY) Climbs 4.25% to $0.83 as Small-Cap Biotech Finds BuyersRetracement Entry - vinanet.vn
ONCY Q3 2025 Earnings: Wider Loss Misses Estimates, Stock Still Rises 4.25%Cost Structure Review - vinanet.vn
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech (ONCY) Holds Near $0.82 as Shares Edge Up 0.49%Entry Point Alerts - vinanet.vn
Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
ONCY: Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources - TradingView
Oncolytics net loss widens to $9.44 million in Q2 2026; R&D expenses more than doubled to $4.26 million - Bitget
Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday - MarketBeat
Why Overall Survival May Be Becoming Oncology’s Most Important Metric (NASDAQ: ONCY) - Barchart.com
Oncolytics Biotech | 10-Q: Q1 2026 Earnings Report - Moomoo
Oncolytics Biotech (NASDAQ:ONCY) Trading Up 0.2%Time to Buy? - MarketBeat
ONCY Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice - TradingView
Oncolytics Biotech Inc (ONCY) Balance Sheet - TradingKey
Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.810|Chg%:-0.002 - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.812|Chg%:-0.036 - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.784|Chg%:-0.016 - TradingKey
Oncolytics Biotech Faces Nasdaq Minimum Bid Price Noncompliance - The Globe and Mail
Oncolytics Biotech Inc. (ONCY) Files 8-K Notice of Nasdaq Delisting or Listing Rule Deficiency – July 2026 - Minichart
Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
ONCY Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oncolytics (ONCY) Receives FDA Fast Track Designation for Pelare - GuruFocus
Viral Immunotherapy Gets FDA Fast Track for Anal Cancer Patients Without Options - Tech Times
Oncolytics wins US FDA Fast Track for pelareorep in anal cancer - AllSci
FDA grants fast track status to Oncolytics’ anal cancer therapy By Investing.com - Investing.com South Africa
Oncolytics Biotech Gets US FDA Fast Track Designation for Pelareorep Combination in Anal Cancer Treatment - marketscreener.com
0.86%
0.31%
자본화:
|
볼륨(24시간):